Our Alliance
By bridging between the commercial and non-profit sectors, we can bend the survival curve faster and improve outcomes. Our diverse perspectives help us identify and target needs more precisely, while our depth of resources amplify our impact.
Our founding partners represent patient organizations, scientific and medical societies, and industry, and together, our perspectives and expertise will help us reach our ambition.
The time for change is now. It is our responsibility as members of the lung cancer community to overcome the barriers that stand in the way of optimal care. Together, we will move faster for lung cancer patients: prioritizing screening, quality care and the delivery of treatments that can be administered earlier in the course of the disease.”
Dave Fredrickson,
EVP, Oncology Business Unit, AstraZeneca
Lung cancer is a highly personal disease, and care approaches can vary widely around the world. By joining together with partners who have distinct but complementary areas of focus in lung cancer, we are better positioned than ever before to address the issues patients face along the lung cancer journey at the country and even individual level.”
Jesme Fox,
Secretary, GLCC
Lung cancer remains the leading cause of cancer death globally. We must do better. By being part of the Lung Ambition Alliance, we join other members in bringing united and strengthened focus to advancing innovative approaches to bend the mortality curve of lung cancer which impacts so many. We look forward to making a meaningful contribution to creating a future where cancers are detected much earlier than they are today. Until then, we are committed to helping patients at all stages of the disease live longer and healthier lives.”
Helmy Eltoukhy,
CEO, Guardant Health.
Date of Preparation: April 2026 | Document ID: Z4-81030